Immunome Inc. (IMNM) saw its stock price plummet by 5.08% in Friday's trading session following the release of its full-year 2024 financial results. The biotechnology company reported a significant widening of its net loss and missed analyst expectations, raising concerns among investors about its financial performance and future prospects.
The company reported a net loss of $293.0 million for the full year 2024, representing a substantial 174% increase from the previous year. This translated to a loss of $5.00 per share, which was 14% worse than analyst estimates. Additionally, Immunome's revenue fell short of expectations, missing analyst forecasts by 3.9%.
Despite the disappointing results, analysts remain cautiously optimistic about Immunome's long-term potential. Revenue is forecast to grow at an average rate of 53% per annum over the next three years, outpacing the 20% growth projected for the US Biotechs industry. However, investors will be closely monitoring the company's ability to narrow its losses and achieve its growth targets in the coming quarters.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。